 | |
Native name | Alcon AG |
|---|---|
| Company type | Public (Aktiengesellschaft) |
| Industry | Ophthalmology |
| Founded | 1945 in Fort Worth, Texas, United States |
| Headquarters | , United States |
Key people | David Endicott (CEO) |
| Products | |
| Revenue |  US$9.46 billion (2023) |
| US$1.04 billion (2023) | |
| US$974 million (2023) | |
| Total assets | US$29.6 billion (2023) |
| Total equity | US$20.6 billion (2023) |
Number of employees | 25,315 (FTE, 2023) |
| Website | alcon |
| Footnotes / references [1] | |
Alcon Inc. (‹See Tfd›German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.[2]
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company.[3][4] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.[5]
- ^ "Alcon Inc. 2023 Annual Report (Form 20-F)". SEC.gov. U.S. Securities and Exchange Commission. 2024-02-27.
- ^ Bounds, Jeff (2020-01-22). "The (Alcon) Family Tree: How One Company Seeded a DFW Life Science Legacy". Dallas Innovates. Retrieved 2023-02-28.
- ^ "Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business". Alcon.
- ^ Smith, Anna (2019-04-10). "Novartis continues to 'reimagine' itself, as Alcon spin-off completed". PharmaTimes. Retrieved 2019-04-10.
- ^ "Oberpfälzer Adresse für Augen-Korrektur". www.onetz.de (in German). Retrieved 2020-10-20.